nerlynx
pierre fabre medicament - neratinib - krūties navikai - antinavikiniai vaistai - nerlynx yra nurodyta pratęstas oksaliplatina suaugusių pacientų su anksti hormonų receptorių, her2 teigiamą-overexpressed/papildyta, krūties vėžio ir kurie yra mažiau kaip vienus metus nuo užbaigti iki palaikomosios trastuzumab pagrįstas terapija.
apredonav
medochemie ltd. - ivabradinas - plėvele dengtos tabletės - 5 mg - ivabradine
apredonav
medochemie ltd. - ivabradinas - plėvele dengtos tabletės - 7,5 mg - ivabradine
polsar
zakłady farmaceutyczne polpharma s.a. - tikagreloras - plėvele dengtos tabletės - 60 mg - ticagrelor
polsar
zakłady farmaceutyczne polpharma s.a. - tikagreloras - plėvele dengtos tabletės - 90 mg - ticagrelor
atixarso
krka, d.d., novo mesto - tikagreloras - plėvele dengtos tabletės - 60 mg - ticagrelor
atixarso
krka, d.d., novo mesto - tikagreloras - plėvele dengtos tabletės - 90 mg - ticagrelor
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antinavikiniai vaistai - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.
ticagrelor mylan
viatris limited - tikagreloras - plėvele dengtos tabletės - 90 mg - ticagrelor
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antinavikiniai vaistai - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).